


Abdullah A. Alotaibi, Bakr F. Abdel-Wahab, Amany S. Hegazy, Benson M. Kariuki and Gamal A. El-Hiti*

The crystal structure of 2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-8*H*-indeno[1,2-*d*]thiazole, C₂₅H₁₇BrFN₃S



<https://doi.org/10.1515/ncks-2020-0088>

Received February 14, 2020; accepted March 10, 2020; available online April 9, 2020

Abstract

C₂₅H₁₇BrFN₃S, triclinic, P\bar{1} (no. 2), $a = 11.2926(6)$ Å, $b = 11.5832(4)$ Å, $c = 16.9974(9)$ Å, $\alpha = 109.211(4)^\circ$, $\beta = 90.211(4)^\circ$, $\gamma = 95.290(4)^\circ$, $V = 2089.21(18)$ Å³, $Z = 4$, $R_{\text{gt}}(F) = 0.0580$, $wR_{\text{ref}}(F^2) = 0.1797$, $T = 296$ K.

CCDC no.: 1989338

The asymmetric unit of the title structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1: Data collection and handling.

Crystal:	Yellow plate
Size:	0.31 × 0.23 × 0.05 mm
Wavelength:	Mo Kα radiation (0.71073 Å)
μ :	2.10 mm ⁻¹
Diffractometer, scan mode:	SuperNova, ω
θ_{max} , completeness:	29.8°, >99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	18184, 9828, 0.026
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 5689
$N(\text{param})_{\text{refined}}$:	559
Programs:	CrysAlis ^{PRO} [1], SHELX [2, 3], WinGX/ORTEP [4]

Source of material

The title compound was synthesized from reaction of 3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1*H*-pyrazole-1-carbothioamide (0.76 g, 2.0 mmol) and 2-bromo-2,3-dihydro-1*H*-inden-1-one (1.10 g, 2.0 mmol) in anhydrous ethanol (20 mL) under reflux for 2 h. The solid obtained was collected by filtration, washed with ethanol, dried, and recrystallized from dimethylformamide to give yellow crystals in 75% yield (Mp. 245–247 °C).

Experimental details

All hydrogen atoms were identified in difference Fourier syntheses. The methine, methylene and aromatic ring hydrogens were idealized during refinement using options AFIX 13, AFIX 23 and AFIX 43 respectively in the SHELXL-2018 program [3]. The U_{iso} values of the hydrogen atoms were set to $1.2U_{\text{eq}}(\text{C})$.

Comment

Indeno[1,2-*d*]thiazoles act as A₁ adenosine receptor agonist allosteric enhancers [5] and anorectic agents [6]. Heterocycles containing pyrazole and thiazole moieties are biologically active and show some medicinal activities [7–9]. The most common synthetic methods for pyrazoles involve a treatment of 1,3-difunctional compounds with hydrazines [10], whereas thiazoles are commonly synthesized through Hantzsch, Gabriel, and Cook–Heilborn’s syntheses [11]. Recently, the X-ray crystal structures of related compounds have been reported [12–15].

*Corresponding author: Gamal A. El-Hiti, Cornea Research Chair, Department of Optometry, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia, e-mail: gelhiti@ksu.edu.sa. <https://orcid.org/0000-0001-6675-3126>

Abdullah A. Alotaibi: Department of Chemistry, College of Science and Humanities, Shaqra University, 11911 Al-Dawadmi, Saudi Arabia
Bakr F. Abdel-Wahab: Applied Organic Chemistry Department, National Research Centre, Dokki, Giza 12622, Egypt

Amany S. Hegazy and Benson M. Kariuki: School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	<i>U</i> _{iso} */* <i>U</i> _{eq}
C1	0.7847(3)	-0.9138(3)	-0.0235(3)	0.0449(9)
C2	0.7956(4)	-0.8662(3)	0.0605(3)	0.0496(10)
C3	0.8437(4)	-0.9531(4)	0.0985(3)	0.0579(11)
H3A	0.788957	-0.972712	0.137200	0.070*
H3B	0.920423	-0.920470	0.126766	0.070*
C4	0.8542(3)	-1.0631(3)	0.0213(3)	0.0520(10)
C5	0.8177(3)	-1.0398(3)	-0.0506(3)	0.0474(9)
C6	0.8937(4)	-1.1753(4)	0.0138(4)	0.0643(13)
H6	0.919225	-1.191634	0.060814	0.077*
C7	0.8949(4)	-1.2640(4)	-0.0648(4)	0.0711(15)
H7	0.922093	-1.339470	-0.070144	0.085*
C8	0.8570(4)	-1.2415(4)	-0.1334(4)	0.0684(13)
H8	0.857739	-1.302330	-0.185239	0.082*
C9	0.8165(4)	-1.1285(4)	-0.1280(3)	0.0589(11)
H9	0.789733	-1.113843	-0.175317	0.071*
C10	0.7353(3)	-0.7322(3)	-0.0106(3)	0.0449(9)
C11	0.6999(3)	-0.6294(3)	-0.1168(2)	0.0426(9)
H11	0.651597	-0.700770	-0.154705	0.051*
C12	0.6363(3)	-0.5129(3)	-0.1024(3)	0.0450(9)
H12A	0.674895	-0.460110	-0.130728	0.054*
H12B	0.553341	-0.532903	-0.121040	0.054*
C13	0.6487(3)	-0.4542(3)	-0.0097(2)	0.0414(8)
C14	0.8228(3)	-0.6187(3)	-0.1503(2)	0.0397(8)
C15	0.9256(3)	-0.6046(3)	-0.1016(3)	0.0448(9)
H15	0.919675	-0.603527	-0.046835	0.054*
C16	1.0366(4)	-0.5920(3)	-0.1335(3)	0.0524(10)
H16	1.105346	-0.581839	-0.100666	0.063*
C17	1.0431(4)	-0.5949(4)	-0.2139(3)	0.0565(11)
C18	0.9436(4)	-0.6092(4)	-0.2647(3)	0.0587(11)
H18	0.950311	-0.611258	-0.319593	0.070*
C19	0.8335(4)	-0.6205(4)	-0.2313(3)	0.0515(10)
H19	0.765123	-0.629463	-0.264292	0.062*
C20	0.6190(3)	-0.3308(3)	0.0363(3)	0.0414(8)
C21	0.5708(3)	-0.2606(3)	-0.0061(3)	0.0488(9)
H21	0.560032	-0.292225	-0.063754	0.059*
C22	0.5388(4)	-0.1444(4)	0.0365(3)	0.0543(11)
H22	0.506645	-0.098061	0.007864	0.065*
C23	0.5551(4)	-0.0989(3)	0.1210(3)	0.0527(10)
C24	0.6058(4)	-0.1638(4)	0.1653(3)	0.0557(10)
H24	0.618604	-0.130090	0.222721	0.067*
C25	0.6370(4)	-0.2798(4)	0.1224(3)	0.0513(10)
H25	0.670611	-0.324748	0.151575	0.062*
C26	0.7911(4)	-0.6370(4)	-0.4978(3)	0.0595(11)
C27	0.7786(4)	-0.6799(4)	-0.5812(3)	0.0616(12)
C28	0.8099(5)	-0.5818(4)	-0.6194(3)	0.0730(14)
H28A	0.743381	-0.571018	-0.651702	0.088*
H28B	0.878197	-0.599197	-0.654405	0.088*
C29	0.8386(4)	-0.4718(4)	-0.5418(3)	0.0660(13)
C30	0.8279(4)	-0.5048(4)	-0.4691(3)	0.0596(11)
C31	0.8733(5)	-0.3507(5)	-0.5342(4)	0.0815(17)
H31	0.881020	-0.327248	-0.581403	0.098*
C32	0.8962(5)	-0.2651(5)	-0.4559(4)	0.0879(18)
H32	0.920104	-0.183921	-0.451072	0.105*
C33	0.8846(5)	-0.2968(5)	-0.3847(4)	0.0892(17)
H33	0.899697	-0.237443	-0.332498	0.107*

Table 2 (continued)

Atom	x	y	z	<i>U</i> _{iso} */* <i>U</i> _{eq}
C34	0.8502(5)	-0.4185(4)	-0.3917(4)	0.0738(14)
H34	0.842377	-0.441041	-0.344131	0.089*
C35	0.7345(4)	-0.8260(4)	-0.5101(3)	0.0583(11)
C36	0.6952(4)	-0.9366(4)	-0.4054(3)	0.0540(10)
H36	0.649351	-0.871964	-0.370693	0.065*
C37	0.6235(4)	-1.0623(4)	-0.4234(3)	0.0584(11)
H37A	0.660165	-1.112115	-0.395987	0.070*
H37B	0.542251	-1.053572	-0.405905	0.070*
C38	0.6285(4)	-1.1162(4)	-0.5166(3)	0.0532(10)
C39	0.8161(4)	-0.9272(3)	-0.3643(3)	0.0472(9)
C40	0.8226(4)	-0.9273(4)	-0.2831(3)	0.0561(11)
H40	0.752743	-0.932860	-0.255177	0.067*
C41	0.9309(4)	-0.9194(4)	-0.2426(3)	0.0599(11)
H41	0.934775	-0.919487	-0.187980	0.072*
C42	1.0308(4)	-0.9116(4)	-0.2846(3)	0.0608(11)
C43	1.0302(4)	-0.9117(4)	-0.3645(3)	0.0626(12)
H43	1.101001	-0.906769	-0.391531	0.075*
C44	0.9214(4)	-0.9192(4)	-0.4045(3)	0.0535(10)
H44	0.918958	-0.918875	-0.459169	0.064*
C45	0.5863(4)	-1.2433(4)	-0.5670(3)	0.0522(10)
C46	0.5211(4)	-1.3196(4)	-0.5316(3)	0.0631(12)
H46	0.506257	-1.291512	-0.475032	0.076*
C47	0.4778(5)	-1.4382(4)	-0.5803(3)	0.0705(13)
H47	0.431153	-1.488225	-0.557087	0.085*
C48	0.5042(4)	-1.4803(4)	-0.6624(3)	0.0598(11)
C49	0.5717(5)	-1.4096(4)	-0.6979(3)	0.0724(14)
H49	0.590483	-1.440813	-0.753709	0.087*
C50	0.6126(5)	-1.2908(4)	-0.6507(3)	0.0677(13)
H50	0.658327	-1.241867	-0.675138	0.081*
N1	0.7501(3)	-0.8388(3)	-0.0660(2)	0.0454(8)
N2	0.7015(3)	-0.6367(3)	-0.0326(2)	0.0472(8)
N3	0.6834(3)	-0.5267(3)	0.0282(2)	0.0428(7)
N4	0.7652(3)	-0.7184(3)	-0.4544(2)	0.0593(9)
N5	0.7018(4)	-0.9287(3)	-0.4898(2)	0.0659(11)
N6	0.6692(3)	-1.0389(3)	-0.5523(2)	0.0569(9)
Br1	0.51139(5)	0.06048(4)	0.18048(4)	0.0835(2)
Br2	0.44554(6)	-1.64283(5)	-0.72785(4)	0.0974(2)
S1	0.76099(10)	-0.71559(9)	0.09420(7)	0.0530(3)
S2	0.73495(12)	-0.83545(11)	-0.61521(8)	0.0671(3)
F1	1.1517(2)	-0.5866(3)	-0.2468(2)	0.0849(9)
F2	1.1384(3)	-0.8993(3)	-0.2442(2)	0.0937(10)

The asymmetric unit of the title structure consists of two independent molecules (see the figure). The molecule comprises indenothiazolyl (**A**₁[C1—C10,N1,S1] and **A**₂[C26—C35,N4,S2]), pyrazolyl (**B**₁[C11—C13,N2,N3] and **B**₂[C36—C38,N5,N6]), bromophenyl (**C**₁[C20—C25,Br1] and **C**₂[C45—C50,Br2]) and fluorophenyl (**D**₁[C14—C19,F1] and **D**₂[C39—C44,F2]) ring systems. In both molecules, ring systems **A**, **B** and **C** are almost coplanar with twist angles **A**₁/**B**₁ = 6.63(15)^o and **B**₁/**C**₁ = 7.48(18)^o for one molecule and **A**₂/**B**₂ = 11.13(21)^o and **B**₂/**C**₂ = 14.35(20)^o for the other molecule. The interplanar angle between the fluorophenyl and pyrazolyl rings are

B₁/D₁ = 71.64(13)^o and **B₂/D₂** = 66.35(15)^o. In the crystal, a number of rings are involved in $\pi \cdots \pi$ interactions. The rings of the fluorophenyl groups of one type of molecule are parallel with a D₂ · · · D₂ centroid separation of 3.62 Å. The indeno-thiazolyl groups are also parallel with centroid separations A₁ · · · A₁ = 4.18 Å and A₂ · · · A₂ = 4.21 Å. The indeno-thiazolyl group of one molecule and the bromophenyl group of the other are also parallel with A₁ · · · C₁ a centroid separation of 4.15 Å. Two molecules of one type are linked by a pair of C16—H16 · · · N3 contacts.

Acknowledgements: The authors are grateful to the Deanship of Scientific Research, King Saud University for funding through Vice Deanship of Scientific Research Chairs.

References

1. Agilent Technologies: CrysAlis^{PRO} Software system, version 1.171.35.15, Agilent Technologies UK Ltd, Oxford, UK (2011).
2. Sheldrick, G. M.: A short history of SHELX. *Acta Crystallogr. A* **64** (2008) 112–122.
3. Sheldrick, G. M.: Crystal structure refinement with SHELXL. *Acta Crystallogr. C* **71** (2015) 3–8.
4. Farrugia, L. J.: WinGX and ORTEP for Windows: an update. *J. Appl. Crystallogr.* **45** (2012) 849–854.
5. Chordia, M. D.; Zigler, M.; Murphree, L. J.; Figler, H.; Macdonald, T. L.; Olsson, R. A.; Linden, J.: 6-Aryl-8*H*-indeno[1,2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency. *J. Med. Chem.* **48** (2005) 5131–5139.
6. Zhou, M.; Ning, C.; Liu, R.; He, Y.; Yu, N.: Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors. *Bioorg. Med. Chem. Lett.* **23** (2013) 3200–3203.
7. Taherkhorsand, H.; Nikpassand, M.: One-pot synthesis of novel 2-pyrazolo-3-phenyl-1,3-thiazolidine-4-ones using DSDAB-COC as an effective media. *Comb. Chem. High Throughput Screening* **21** (2018) 65–69.
8. Sravya, G.; Yamini, G.; Padmavathi, V.; Padmaja, A.: Synthesis and antimicrobial activity of styryl/pyrrolyl/pyrazolyl sulfonylmethyl-1,3,4-oxadiazolyl amines and styryl/pyrrolyl/pyrazolyl sulfonylmethyl-1,3,4-thiadiazolyl amines. *Eur. J. Med. Chem.* **21** (2016) 647–655.
9. Abdel-Wahab, B. F.; Abdel-Latif, E.; Mohamed, H. A.; Awad, G. E.: Design and synthesis of new 4-pyrazolin-3-yl-1,2,3-triazoles and 1,2,3-triazol-4-yl-pyrazolin-1-ylthiazoles as potential antimicrobial agents. *Eur. J. Med. Chem.* **52** (2012) 263–268.
10. Yet, L.: Vol. 4: Five-membered rings with two heteroatoms, each with their fused carbocyclic derivatives: pyrazoles. In *Comprehensive Heterocyclic Chemistry III* (Eds. A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven, R. J. K. Taylor), p. 1–141. Elsevier Ltd., Amsterdam, Netherlands (1996).
11. Maienfisch, P.; Edmunds, A. J. F.: Chapter three – thiazole and isothiazole ring-containing compounds in crop protection. In *Advances in Heterocyclic Chemistry. Vol. 121: Heterocyclic Chemistry in the 21st Century: A Tribute to Alan Katritzky* (Eds. E. F. V. Scriven, C. A. Ramsden), p. 35–88. Elsevier Inc., Cambridge, MA, USA (2017).
12. Alotaibi, M. H.; Abdel-Wahab, B. F.; Yousif, E.; Hegazy, A. S.; Kariuki, B. M.; El-Hiti, G. A.: Crystal structure of 3-(2-(5-(4-fluorophenyl)-3-(4-methylphenyl)-4,5-dihydro-1*H*-pyrazol-1-yl)thiazol-4-yl)-2*H*-chromen-2-one, C₂₈H₂₀FN₃O₂S. *Z. Kristallogr. NCS* **235** (2020) 469–471.
13. El-Hiti, G. A.; Abdel-Wahab, B. F.; Hegazy, A. S.; Kariuki, B. M.: Crystal structure of (*E*)-2-(5-(4-fluorophenyl)-3-(furan-2-yl)-4,5-dihydro-1*H*-pyrazol-1-yl)-5-((4-fluorophenyl)diazenyl)-4-methylthiazole, C₂₃H₁₇F₂N₅OS. *Z. Kristallogr. NCS* **232** (2017) 469–471.
14. El-Hiti, G. A.; Abdel-Wahab, B. F.; Baashen, M.; Hegazy, A. S.; Kariuki, B. M.: Crystal structure of (*E*)-5-((4-chlorophenyl)diazenyl)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1*H*-pyrazol-1-yl)-4-methylthiazole, C₂₃H₁₇ClFN₅S₂. *Z. Kristallogr. NCS* **232** (2017) 157–158.
15. Ghabbour, H. A.; Abdel-Wahab, B. F.; Alamri, M.; Al-Omar, M. A.; El-Hiti, G. A.: Crystal structure of 2-(5-(4-fluorophenyl)-3-*p*-tolyl-4,5-dihydro-1*H*-pyrazol-1-yl)-4-(5-methyl-1-*p*-tolyl-1*H*-1,2,3-triazol-4-yl)thiazole, C₂₉H₂₅FN₆S. *Z. Kristallogr. NCS* **232** (2017) 21–23.